TY - JOUR
T1 - HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer
AU - Fukumoto, Takeshi
AU - Fatkhutdinov, Nail
AU - Zundell, Joseph A.
AU - Tcyganov, Evgenii N.
AU - Nacarelli, Timothy
AU - Karakashev, Sergey
AU - Wu, Shuai
AU - Liu, Qin
AU - Gabrilovich, Dmitry I.
AU - Zhang, Rugang
N1 - Publisher Copyright:
© 2019 Phcogj.Com.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - ARID1A, encoding a subunit of the SWI/SNF complex, is the most frequently mutated epigenetic regulator in human cancers and is mutated in more than 50% of ovarian clear cell carcinomas (OCCC), a disease that currently has no effective therapy. Inhibition of histone deacetylase 6 (HDAC6) suppresses the growth of ARID1A-mutated tumors and modulates tumor immune microenvironment. Here, we show that inhibition of HDAC6 synergizes with anti-PD-L1 immune checkpoint blockade in ARID1A-inactivated ovarian cancer. ARID1A directly repressed transcription of CD274, the gene encoding PD-L1. Reduced tumor burden and improved survival were observed in ARID1Aflox/flox/PIK3CAH1047R OCCC mice treated with the HDAC6 inhibitor ACY1215 and anti-PD-L1 immune checkpoint blockade as a result of activation and increased presence of IFNγ positive CD8 T cells. We confirmed that the combined treatment limited tumor progression in a cytotoxic T-cell-dependentmanner, as depletion of CD8+ T cells abrogated these antitumor effects. Together, these findings indicate that combined HDAC6 inhibition and immune checkpoint blockade represents a potential treatment strategy for ARID1A-mutated cancers.
AB - ARID1A, encoding a subunit of the SWI/SNF complex, is the most frequently mutated epigenetic regulator in human cancers and is mutated in more than 50% of ovarian clear cell carcinomas (OCCC), a disease that currently has no effective therapy. Inhibition of histone deacetylase 6 (HDAC6) suppresses the growth of ARID1A-mutated tumors and modulates tumor immune microenvironment. Here, we show that inhibition of HDAC6 synergizes with anti-PD-L1 immune checkpoint blockade in ARID1A-inactivated ovarian cancer. ARID1A directly repressed transcription of CD274, the gene encoding PD-L1. Reduced tumor burden and improved survival were observed in ARID1Aflox/flox/PIK3CAH1047R OCCC mice treated with the HDAC6 inhibitor ACY1215 and anti-PD-L1 immune checkpoint blockade as a result of activation and increased presence of IFNγ positive CD8 T cells. We confirmed that the combined treatment limited tumor progression in a cytotoxic T-cell-dependentmanner, as depletion of CD8+ T cells abrogated these antitumor effects. Together, these findings indicate that combined HDAC6 inhibition and immune checkpoint blockade represents a potential treatment strategy for ARID1A-mutated cancers.
UR - http://www.scopus.com/inward/record.url?scp=85074377186&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074377186&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-19-1302
DO - 10.1158/0008-5472.CAN-19-1302
M3 - Article
C2 - 31311810
AN - SCOPUS:85074377186
SN - 0008-5472
VL - 79
SP - 5482
EP - 5489
JO - Cancer Research
JF - Cancer Research
IS - 21
ER -